CSF1R and neuroblastoma: Despite the relevance of the adenosine pathway in neuroblastoma, treatment of TH-MYCN mice with a combination of anti-PD-1 and anti-CD73 antibodies did not lead to tumor growth inhibition, and a triple combination with CSF-1R inhibitor BLZ945 had to be discontinued due to severe weight loss in mice.